scholarly journals A case of Behcet's disease with esophageal ulcers complicated with systemic sclerosis, chronic hepatitis C, and pancytopenia

2004 ◽  
Vol 27 (3) ◽  
pp. 164-170 ◽  
Author(s):  
Kazuhiro YOKOTA ◽  
Motoharu HIRANO ◽  
Haruhiko AKIBA ◽  
Daisuke ADACHI ◽  
Michio TAKEISHI ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Systemic Sclerosis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Behcet's Disease ◽  
Esophageal Ulcers

scholarly journals Therapeutic options for patients with rare rheumatic diseases: a systematic review and meta-analysis

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Tim T. A. Bender ◽  
Judith Leyens ◽  
Julia Sellin ◽  
Dmitrij Kravchenko ◽  
Rupert Conrad ◽  
...  
Keyword(s):  
Systematic Review ◽  
Systemic Sclerosis ◽  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Behcet's Disease ◽  
Randomized Controlled ◽  
Anca Associated Vasculitis

Abstract Background Rare diseases (RDs) in rheumatology as a group have a high prevalence, but randomized controlled trials are hampered by their heterogeneity and low individual prevalence. To survey the current evidence of pharmacotherapies for rare rheumatic diseases, we conducted a systematic review and meta-analysis. Randomized controlled trials (RCTs) of RDs in rheumatology for different pharmaco-interventions were included into this meta-analysis if there were two or more trials investigating the same RD and using the same assessment tools or outcome parameters. The Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and PUBMED were searched up to April 2nd 2020. The overall objective of this study was to identify RCTs of RDs in rheumatology, evaluate the overall quality of these studies, outline the evidence of pharmacotherapy, and summarize recommended therapeutic regimens. Results We screened 187 publications, and 50 RCTs met our inclusion criteria. In total, we analyzed data of 13 different RDs. We identified several sources of potential bias, such as a lack of description of blinding methods and allocation concealment, as well as small size of the study population. Meta-analysis was possible for 26 studies covering six RDs: Hunter disease, Behçet’s disease, giant cell arteritis, ANCA-associated vasculitis, reactive arthritis, and systemic sclerosis. The pharmacotherapies tested in these studies consisted of immunosuppressants, such as corticosteroids, methotrexate and azathioprine, or biologicals. We found solid evidence for idursulfase as a treatment for Hunter syndrome. In Behçet’s disease, apremilast and IF-α showed promising results with regard to total and partial remission, and Tocilizumab with regard to relapse-free remission in giant cell arteritis. Rituximab, cyclophosphamide, and azathioprine were equally effective in ANCA-associated vasculitis, while mepolizumab improved the efficacy of glucocorticoids. The combination of rifampicin and azithromycin showed promising results in reactive arthritis, while there was no convincing evidence for the efficacy of pharmacotherapy in systemic sclerosis. Conclusion For some diseases such as systemic sclerosis, ANCA-associated vasculitis, or Behcet's disease, higher quality trials were available. These RCTs showed satisfactory efficacies for immunosuppressants or biological drugs, except for systemic sclerosis. More high quality RCTs are urgently warranted for a wide spectrum of RDs in rheumatology.

A case of Behçet’s disease with esophageal ulcers

2019 ◽  
Vol 89 (2) ◽  
pp. 430-431
Author(s):  
Yuko Sakakibara ◽  
Shoichi Nakazuru ◽  
Tomofumi Akasaka ◽  
Hisashi Ishida ◽  
Eiji Mita
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Behcet's Disease ◽  
Esophageal Ulcers

Examination of the Relationship between the Hepatitis C Virus and Behçet's Disease

2004 ◽  
Vol 31 (5) ◽  
pp. 442-443 ◽  
Author(s):  
Meral Sönmezoglu ◽  
Emine Derviş ◽  
Selim Badur ◽  
O.Şadi Yenen
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Behcet's Disease ◽  
The Relationship

Development of systemic sclerosis in patients with Behçet's disease: Remission of Behçet's disease in parallel with the progression of skin sclerosis

2014 ◽  
Vol 41 (12) ◽  
pp. 1113-1114
Author(s):  
Yohei Ichimura ◽  
Yoshihide Asano ◽  
Takehiro Takahashi ◽  
Tetsuo Toyama ◽  
Takashi Taniguchi ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Behcet's Disease ◽  
Disease Remission ◽  
Skin Sclerosis

Contribution of the Rho-kinase to Systemic Sclerosis and Behçet’s Disease

2018 ◽  
Vol 24 (29) ◽  
pp. 3402-3409
Author(s):  
Seniz Demiryürek ◽  
Elif Baysalman ◽  
Azad Mammadov ◽  
Abdullah T. Demiryürek
Keyword(s):  
Systemic Sclerosis ◽  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Inflammatory Responses ◽  
Behçet's Disease ◽  
Rho Kinase ◽  
Small Gtpase ◽  
Current Evidence ◽  
Behcet's Disease ◽  
Cell Contractility

Background: The small GTPase Rho family and its effectors, Rho-kinases (ROCK) play essential roles in the actin cytoskeleton organization and coordinate a broad range of cellular functions, such as inflammatory responses, cell contractility, migration, adhesion, proliferation, and apoptosis. Methods: : The goal of this work is to review existing literature about systemic sclerosis and Behçet’s disease in relation to ROCK. <p> Results: There are some evidence that ROCK expression is elevated in patients with systemic sclerosis and Behçet’s disease. Rho/ROCK gene polymorphisms have been shown to be associated with these disorders. Endothelial function is also impaired in these autoimmune diseases. Rho/Rho-kinase pathway might have a crucial role in endothelial, vascular, and fibrotic pathologies. Conclusion: Dysregulation in the Rho/ROCK pathway may represent a common pathogenic mechanism in multiple autoimmune disorders. Current evidence indicate that Rho/ROCK genes might be risk factors, and can contribute to susceptibility and development of systemic sclerosis and Behçet’s disease. These studies may also provide important insights into the future development or use of potential novel therapeutic approaches, such as selective Rho-kinase inhibitors, for the treatment of patients with systemic sclerosis and Behçet’s disease.

Sign in / Sign up

Export Citation Format

Share Document